Category: News

4 posts

Prokarium secures $10 million investment from Saudi, Swedish and Korean investors for clinical development of revolutionary thermostable vaccines

Keele, UK, Riyadh, KSA, Stockholm, SE, and Seoul, KR; 26th February 2018 - Prokarium, the UK-based synthetic biology company that has developed Vaxonella, an oral, Read more Prokarium secures $10 million investment from Saudi, Swedish and Korean investors for clinical development of revolutionary thermostable vaccines

Prokarium to present at ‘Future Challenges of Manufacturing Biopharmaceuticals’ conference, 30th Nov. 2016, London

Prokarium's Chief Scientific Officer, Dr Rocky Cranenburgh, will discuss the innovative manufacturing technologies developed to support the Vaxonella platform at this 'Genesis Fringe' event at Read more Prokarium to present at ‘Future Challenges of Manufacturing Biopharmaceuticals’ conference, 30th Nov. 2016, London